Eric A F SimÃµes

List of Publications by Year
in descending order

77 papers	8,068 citations	186265 28 h-index	82547 72 g-index
79 all docs	79 docs citations	79 times ranked	7132 citing authors

#	Article	IF	Citations
1	Global burden of acute lower respiratory infections due to respiratory syncytial virus in young children: a systematic review and meta-analysis. Lancet, The, 2010, 375, 1545-1555.	13.7	2,308
2	Global, regional, and national disease burden estimates of acute lower respiratory infections due to respiratory syncytial virus in young children in 2015: a systematic review and modelling study. Lancet, The, 2017, 390, 946-958.	13.7	1,634
3	Prophylactic Administration of Respiratory Syncytial Virus Immune Globulin to High-Risk Infants and Young Children. New England Journal of Medicine, 1993, 329, 1524-1530.	27.0	748
4	Global, regional, and national disease burden estimates of acute lower respiratory infections due to respiratory syncytial virus in children younger than 5 years in 2019: a systematic analysis. Lancet, The, 2022, 399, 2047-2064.	13.7	445
5	Respiratory syncytial virus epidemics: the ups and downs of a seasonal virus. Pediatric Infectious Disease Journal, 2003, 22, S21-S32.	2.0	212
6	Defining the Epidemiology and Burden of Severe Respiratory Syncytial Virus Infection Among Infants and Children in Western Countries. Infectious Diseases and Therapy, 2016, 5, 271-298.	4.0	204
7	The effect of respiratory syncytial virus on subsequent recurrent wheezing in atopic and nonatopic children. Journal of Allergy and Clinical Immunology, 2010, 126, 256-262.	2.9	195
8	Palivizumab Prophylaxis in Preterm Infants and Subsequent Recurrent Wheezing. Six-Year Follow-up Study. American Journal of Respiratory and Critical Care Medicine, 2017, 196, 29-38.	5.6	140
9	The Burden and Long-term Respiratory Morbidity Associated with Respiratory Syncytial Virus Infection in Early Childhood. Infectious Diseases and Therapy, 2017, 6, 173-197.	4.0	133
10	Clinical and Epidemiologic Features of Respiratory Syncytial Virus. Current Topics in Microbiology and Immunology, 2013, 372, 39-57.	1.1	131
11	Chronic Diseases, Chromosomal Abnormalities, and Congenital Malformations as Risk Factors for Respiratory Syncytial Virus Hospitalization: A Population-Based Cohort Study. Clinical Infectious Diseases, 2012, 54, 810-817.	5.8	128
12	Past, Present and Future Approaches to the Prevention and Treatment of Respiratory Syncytial Virus Infection in Children. Infectious Diseases and Therapy, 2018, 7, 87-120.	4.0	112
13	Respiratory syncytial virus neutralizing antibodies in cord blood, respiratory syncytial virus hospitalization, and recurrent wheeze. Journal of Allergy and Clinical Immunology, 2009, 123, 398-403.	2.9	110
14	Duration of Infant Protection Against Influenza Illness Conferred by Maternal Immunization. JAMA Pediatrics, 2016, 170, 840.	6.2	99
15	Respiratory syncytial virus infection: denominator-based studies in Indonesia, Mozambique, Nigeria and South Africa. Bulletin of the World Health Organization, 2004, 82, 914-22.	3.3	81
16	Suptavumab for the Prevention of Medically Attended Respiratory Syncytial Virus Infection in Preterm Infants. Clinical Infectious Diseases, 2021, 73, e4400-e4408.	5.8	77
17	Global burden of acute lower respiratory infection associated with human metapneumovirus in children under 5 years in 2018: a systematic review and modelling study. The Lancet Global Health, 2021, 9, e33-e43.	6.3	71
18	Defining the Risk and Associated Morbidity and Mortality of Severe Respiratory Syncytial Virus Infection Among Preterm Infants Without Chronic Lung Disease or Congenital Heart Disease. Infectious Diseases and Therapy, 2016, 5, 417-452.	4.0	64

#	Article	IF	Citations
19	Down Syndrome and Hospitalizations due to Respiratory Syncytial Virus: AÂPopulation-Based Study. Journal of Pediatrics, 2012, 160, 827-831.e1.	1.8	61
20	Defining the Incidence and Associated Morbidity and Mortality of Severe Respiratory Syncytial Virus Infection Among Children with Chronic Diseases. Infectious Diseases and Therapy, 2017, 6, 383-411.	4.0	60
21	Defining the Risk and Associated Morbidity and Mortality of Severe Respiratory Syncytial Virus Infection Among Infants with Chronic Lung Disease. Infectious Diseases and Therapy, 2016, 5, 453-471.	4.0	56
22	Does respiratory syncytial virus lower respiratory illness in early life cause recurrent wheeze of early childhood and asthma? Critical review of the evidence and guidance for future studies from a World Health Organization-sponsored meeting. Vaccine, 2020, 38, 2435-2448.	3.8	54
23	SENTINEL1: Two-Season Study of Respiratory Syncytial Virus Hospitalizations among U.S. Infants Born at 29 to 35 Weeks' Gestational Age Not Receiving Immunoprophylaxis. American Journal of Perinatology, 2020, 37, 421-429.	1.4	53
24	Defining the Risk and Associated Morbidity and Mortality of Severe Respiratory Syncytial Virus Infection Among Infants with Congenital Heart Disease. Infectious Diseases and Therapy, 2017, 6, 37-56.	4.0	48
25	The Epidemiology of Respiratory Syncytial Virus Lower Respiratory Tract Infections in Children Less than 5 Years of Age in Indonesia. Pediatric Infectious Disease Journal, 2011, 30, 778-784.	2.0	41
26	Establishing Correlates of Protection for Vaccine Development: Considerations for the Respiratory Syncytial Virus Vaccine Field. Viral Immunology, 2018, 31, 195-203.	1.3	40
27	Respiratory Syncytial Virusâ€“Associated Hospitalization Rates among US Infants: A Systematic Review and Meta-Analysis. Journal of Infectious Diseases, 2022, 225, 1100-1111.	4.0	35
28	Global burden of acute lower respiratory infection associated with human parainfluenza virus in children younger than 5 years for 2018: a systematic review and meta-analysis. The Lancet Global Health, 2021, 9, e1077-e1087.	6.3	30
29	Global Respiratory Syncytial Virusâ€“Related Infant Community Deaths. Clinical Infectious Diseases, 2021, 73, S229-S237.	5.8	29
30	Using Mathematical Transmission Modelling to Investigate Drivers of Respiratory Syncytial Virus Seasonality in Children in the Philippines. PLoS ONE, 2014, 9, e90094.	2.5	28
31	Pathogen Chip for Respiratory Tract Infections. Journal of Clinical Microbiology, 2013, 51, 945-953.	3.9	25
32	Challenges in estimating RSV-associated mortality rates. Lancet Respiratory Medicine,the, 2016, 4, 345-347.	10.7	23
33	Underdetection of laboratory-confirmed influenza-associated hospital admissions among infants: a multicentre, prospective study. The Lancet Child and Adolescent Health, 2019, 3, 781-794.	5.6	22
34	Effects of Chronologic Age and Young Child Exposure on Respiratory Syncytial Virus Disease among US Preterm Infants Born at 32 to 35 Weeks Gestation. PLoS ONE, 2016, 11, e0166226.	2.5	21
35	Reopening Schools and the Dynamics of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infections in Israel: A Nationwide Study. Clinical Infectious Diseases, 2021, 73, 2265-2275.	5.8	21
36	Approaches to use the WHO respiratory syncytial virus surveillance platform to estimate disease burden. Influenza and Other Respiratory Viruses, 2020, 14, 615-621.	3.4	20

#	Article	IF	Citations
37	Long-term Assessment of Healthcare Utilization 5 Years After Respiratory Syncytial Virus Infection in US Infants. Journal of Infectious Diseases, 2020, 221, 1256-1270.	4.0	19
38	Mortality From Respiratory Syncytial Virus in Children Under 2 Years of Age: A Prospective Community Cohort Study in Rural Maharashtra, India. Clinical Infectious Diseases, 2021, 73, S193-S202.	5.8	19
39	Characteristics of SARS-CoV-2 Infections in Israeli Children During the Circulation of Different SARS-CoV-2 Variants. JAMA Network Open, 2021, 4, e2124343.	5.9	19
40	WU and KI polyomavirus infections in Filipino children with lower respiratory tract disease. Journal of Clinical Virology, 2016, 82, 112-118.	3.1	18
41	Otitis Media and Its Sequelae in Kenyan Schoolchildren. Journal of the Pediatric Infectious Diseases Society, 2016, 5, 375-384.	1.3	18
42	Immunogenicity and safety of different dosing schedules of trivalent inactivated influenza vaccine in pregnant women with HIV: a randomised controlled trial. Lancet HIV,the, 2020, 7, e91-e103.	4.7	16
43	Comparison of COVID-19 Incidence Rates Before and After School Reopening in Israel. JAMA Network Open, 2021, 4, e217105.	5.9	16
44	Vaccines for the Paramyxoviruses and Pneumoviruses: Successes, Candidates, and Hurdles. Viral Immunology, 2018, 31, 133-141.	1.3	15
45	Clinical Endpoints for Respiratory Syncytial Virus Prophylaxis Trials in Infants and Children in High-income and Middle-income Countries. Pediatric Infectious Disease Journal, 2015, 34, 1086-1092.	2.0	14
46	Insurance Status and the Risk of Severe Respiratory Syncytial Virus Disease in United States Preterm Infants Born at 32â€“35 Weeks Gestational Age. Open Forum Infectious Diseases, 2016, 3, ofw163.	0.9	14
47	Otitis media related hearing loss in Indonesian school children. International Journal of Pediatric Otorhinolaryngology, 2019, 125, 44-50.	1.0	13
48	Economic-Burden Trajectories in Commercially Insured US Infants With Respiratory Syncytial Virus Infection. Journal of Infectious Diseases, 2019, 221, 1244-1255.	4.0	13
49	Intent to obtain pediatric influenza vaccine among mothers in four middle income countries. Vaccine, 2020, 38, 4325-4335.	3.8	13
50	The Outpatient Burden of Respiratory Syncytial Virus Infections in Older Children. Journal of Infectious Diseases, 2017, 215, 1-3.	4.0	12
51	Contribution of Serologic Assays in the Evaluation of Influenza Virus Infection Rates and Vaccine Efficacy in Pregnant Women: Report From Randomized Controlled Trials. Clinical Infectious Diseases, 2017, 64, 1773-1779.	5.8	12
52	Stateâ€level estimates of excess hospitalizations and deaths associated with influenza. Influenza and Other Respiratory Viruses, 2020, 14, 111-121.	3.4	12
53	Intrafamilial Spread and Altered Symptomatology of SARS-CoV-2, During Predominant Circulation of Lineage B.1.1.7 Variant in Israel. Pediatric Infectious Disease Journal, 2021, 40, e310-e311.	2.0	10
54	Quantifying the Population-Level Effect of the COVID-19 Mass Vaccination Campaign in Israel: A Modeling Study. Open Forum Infectious Diseases, 2022, 9, ofac087.	0.9	10

#	Article	IF	Citations
55	Live attenuated influenza vaccine tetravalent: a clinical review. Expert Review of Vaccines, 2015, 14, 963-973.	4.4	9
56	Lay Field-workerâ€“Led School Health Program for Primary Schools in Low- and Middle-Income Countries. Pediatrics, 2019, 143, .	2.1	9
57	Respiratory syncytial virus and influenza hospitalizations in Danish children 2010â€“2016. Vaccine, 2021, 39, 4126-4134.	3.8	8
58	The Burden of Respiratory Syncytial Virus in Children Under 2 Years of Age in a Rural Community in Maharashtra, India. Clinical Infectious Diseases, 2021, 73, S238-S247.	5.8	8
59	Respiratory Syncytial Virus Disease in Young Children and Older Adults in Europe: A Burden and Economic Perspective. Journal of Infectious Diseases, 0, , .	4.0	8
60	Disease mapping for informing targeted health interventions: childhood pneumonia in Bohol, Philippines. Tropical Medicine and International Health, 2015, 20, 1525-1533.	2.3	7
61	Trivalent influenza vaccination randomized control trial of pregnant women and adverse fetal outcomes. Vaccine, 2019, 37, 5397-5403.	3.8	7
62	Influenza and respiratory syncytial virus in infants study (IRIS) of hospitalized and non-ill infants aged <1 year in four countries: study design and methods. BMC Infectious Diseases, 2017, 17, 222.	2.9	6
63	Anti-SARS-CoV-2 IgA Identifies Asymptomatic Infection in First Responders. Journal of Infectious Diseases, 2022, 225, 578-586.	4.0	6
64	Motavizumab, RSV, and subsequent wheezing. Lancet Infectious Diseases, The, 2016, 16, 639-640.	9.1	5
65	Demographic and ecological risk factors for human influenza A virus infections in rural Indonesia. Influenza and Other Respiratory Viruses, 2017, 11, 425-433.	3.4	5
66	A Child With Intermittent Headaches and Eosinophilic Meningitis. Journal of the Pediatric Infectious Diseases Society, 2018, 7, 355-357.	1.3	4
67	RSV prevention in infancy and asthma in later life. Lancet Respiratory Medicine,the, 2018, 6, e30.	10.7	4
68	Single-dose nirsevimab prevents RSV infection. Journal of Pediatrics, 2021, 228, 310-313.	1.8	4
69	Evaluation of rates of laboratory-confirmed influenza hospitalization in rural and urban census tracts over eight influenza seasons. Preventive Medicine, 2020, 139, 106184.	3.4	3
70	Intensive Care Unit Admission Rates for Respiratory Syncytial Virus Infection as a Function of Age in Preterm Infants Born at 32â€“35-week Gestation and Not Receiving Immunoprophylaxis. Pediatric Infectious Disease Journal, 2015, 34, 331.	2.0	2
71	Acute wheeze in the pediatric population: Case definition & guidelines for data collection, analysis, and presentation of immunization safety data. Vaccine, 2019, 37, 392-399.	3.8	2
72	Adult Population Coverage With Influenza Vaccine and Influenza Hospitalization Ratesâ€”Is There a Role for Active Outreach to Immunize At-Risk Neighborhoods?. Clinical Infectious Diseases, 2021, 73, 1110-1112.	5.8	1

#	Article	IF	Citations
73	Palivizumab. Drugs, 1999, 58, 312-313.	10.9	0
74	Comparison of microarray-predicted closest genomes to sequencing for poliovirus vaccine strain similarity and influenza A phylogeny. Diagnostic Microbiology and Infectious Disease, 2016, 84, 203-206.	1.8	0
75	Population-based otoscopic and audiometric assessment of a birth cohort recruited for a pneumococcal vaccine trial 15â€“18 years earlier: a protocol. BMJ Open, 2021, 11, e042363.	1.9	0
76	1719. Respiratory Syncytial Virus-Associated Hospitalization Rates among US Infants: A Systematic Review and Meta-Analysis. Open Forum Infectious Diseases, 2020, 7, S843-S843.	0.9	0
77	Comparison of the medical burden of COVIDâ€19 with seasonal influenza and measles outbreaks. Acta Paediatrica, International Journal of Paediatrics, 2022, 111, 595-601.	1.5	0